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Background. Pregnancy-associated malaria (PAM) produces poor birth outcomes, but its prevalence is
commonly estimated in convenience samples.
Methods. We assessed the prevalence of malaria using real-time polymerase chain reaction (PCR) and
estimated the consequences of infection on birth outcomes, using specimens from a nationally representative
sample of 4570 women of childbearing age (WOCBA) responding to the 2007 Demographic and Health Survey in
Democratic Republic of the Congo (DRC).
Results. Overall, 31.2% (95% confidence interval [CI], 29.2–33.1) of WOCBA were parasitemic, which was
significantly more common in pregnant (37.2% [31.0–43.5]) than nonpregnant women (30.4% [CI, 28.4–32.5],
prevalence ratio [PR] 1.22 [1.02–1.47]). Plasmodium falciparum was highest among pregnant women (36.6% vs
28.8%, PR 1.27 [1.05–1.53]). By contrast, P malariae was less common in pregnant (0.6%) compared with
nonpregnant women (2.7%, PR 0.23 [0.09–0.56]). Extrapolation of the prevalence estimate to the population at risk
of malaria in DRC suggests 1.015 million births are affected by P falciparum infection annually, and that adherence
to preventive measures could prevent up to 549 000 episodes of pregnancy-associated malaria and 47 000 low-birth-
weight births.
Conclusions. Pregnancy-associated malaria and its consequences are highly prevalent in the DRC. Increasing
the uptake of malaria preventive measures represents a significant opportunity to improve birth outcomes and
neonatal health.
Pregnancy-associated malaria (PAM) is the most im-
portant preventable cause of poor birth outcomes in
sub–Saharan Africa [1]. Most malaria-endemic coun-
tries have adopted PAM-prevention measures such as
insecticide-treated bednets (ITNs) use and intermittent
preventive therapy during pregnancy with sulfadoxine-
pyrimethamine (IPTp-SP) [2, 3]. Both ITNs and IPTp-SP
are clinically and cost-effective interventions to prevent
PAM-associated low birth-weight (LBW) [4–7]. Am-
bitious targets are endorsed for near-universal de-
ployment of these interventions [8], though uptake in
sub–Saharan Africa is inadequate [3].
Nationally representative estimates of PAM preva-
lence are lacking owing to a dearth of surveys that utilize
scientific probability sampling of a random sample of
the entire population. Thus, current estimates of burden
are typically derived from convenience samples that do
not reflect national populations. In malaria-endemic
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sub–Saharan Africa, a recent spatial demographic study esti-
mated that 31 million pregnancies occur annually that result in
approximately 23 million live births [9]. The prevalence of
malaria during pregnancy is reported as high as 25%–28%
[10, 11], but more sensitive parasite detection methods using
polymerase chain reaction (PCR) suggest that the true preva-
lence may be considerably higher [12–14].
The Democratic Republic of the Congo (DRC) has the
second-highest population at risk of malaria in Africa [15] and
over 3.5 million annual pregnancies at risk [3, 9], but there are
no data on the prevalence of malaria parasitemia among preg-
nant and nonpregnant women of childbearing age (WOCBA).
Herein, we describe the first nationally representative, cross-
sectional molecular survey of pregnancy-associated malaria.
Using specimens collected during the 2007 Demographic and
Health Survey (DHS) in DRC, we employed real-time PCR to
estimate both the burden of infection and the birth con-
sequences of PAM in this highly endemic region.
MATERIALS AND METHODS
Ethics Statement
Study procedures were approved by the review boards of Macro
International, the University of Kinshasa School of Public
Health, and the University of North Carolina. All survey re-
spondents provided informed consent verbally owing to the
need for immediate deidentification of all data.
Survey Design and Sample Collection
The DHS surveyed women aged 15 to 49 years within 300
geographic clusters randomly selected from demographic pop-
ulation density data obtained before the 2006 national elections
(Figure 1) [16]. From these clusters, 9000 households were
randomly selected for inclusion, in which all women were sur-
veyed. The survey was designed to collect blood samples in order
to determine human immunodeficiency virus (HIV) serostatus
and measure hemoglobin (Hgb) levels of women from every
other household. Pregnancy status and estimated trimester were
determined by self-report. Clusters near Kinshasa were surveyed
during the rainy season in February and March; the difficulty of
transportation necessitated surveying outlying clusters during
the dry season between May and August.
After consent was obtained, a fingerprick was taken for he-
moglobin assessment and dried blood spots (DBSs). HIV was
determined by enzyme-linked immunosorbent assay and
Western blot testing. Hemoglobin point-of-care testing was
performed using a HemoCue photometer. Hemoglobin results
were immediately communicated to participants, and those
Figure 1. Geographic clusters in Democratic Republic of the Congo in which women of childbearing age were sampled for survey.
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with moderate to severe anemia (Hgb, 9 g/dL or, 7 g/dL for
pregnant and nonpregnant women, respectively) were referred
to local health care services. DBSs were stored at room tem-
perature in individual bags prior to PCR testing.
Molecular Testing
Real-time PCR testing has been described in detail elsewhere [17].
Briefly, testing employed 2 assays that target the 18S ribosomal
DNA sequence of Plasmodia in order to distinguish between
Plasmodium falciparum, P. malariae, and P. ovale. To minimize
the risk of sample contamination, filtered pipet tips were exclu-
sively employed in all steps, and separate work areas were main-
tained for punching discs from DBSs, extracting genomic DNA,
preparing reaction mixtures, and assembling reaction plates.
Statistical Analyses
The overall and species-specific prevalence of parasitemia were
calculated for the overall sample and in pregnant and non-
pregnant women. The species distributions of parasitemias were
compared with Fisher exact test between pregnant and non-
pregnant WOCBA. To determine the effect of pregnancy and
other risk factors on the risk of malaria parasitemia, adjusted
prevalence ratios (aPRs) for parasitemias and anemia were cal-
culated using robust Poisson regression models with pregnancy
as the exposure variable of interest using the overall sample.
Separate models of risk factors were then developed forWOCBA
and pregnant women. Independent variables with prevalence
ratios (PRs) for parasitemia significant at a level of 0.2 were
included in the multivariate models. In addition, known de-
terminants of parasitemia risk were included in the full model
irrespective of bivariate statistical significance.
The contribution of malaria parasitemia to maternal anemia
was assessed in separate Poisson models using a similar ap-
proach, but with anemia (defined as Hgb , 11 g/dL, adjusted
for altitude) as the outcome variable and with malaria and
common risk factors as the exposure variable and covariates.
Because parasitemia was the main exposure of interest, it was
always included in the final multivariate model. For this analysis,
severe anemia was defined as Hgb , 7 g/dL.
All statistical analyses were performed with Stata/IC (v10,
Stata Corp, College Station, TX). All statistical analyses in-
corporated survey sampling weights to account for survey de-
sign in generating nationally representative estimates.
Extrapolation to Annual Number of Pregnancies Affected and
Impact of Malaria Control
The nationally representative sample provided the opportunity
to estimate (1) the total annual number of pregnancies affected
by malaria in DRC, and (2) the potential impact of successful
malaria control by ITNs and IPTp-SP (Figure 2). The lack of
reliable estimates of the risk of mortality attributable to LBW in
sub–Saharan Africa precluded an extrapolated estimate of PAM-
associated infant mortality.
To obtain estimates of the number of pregnancies per year
and the number of births per year, we used the national esti-
mates of the annual number of live births for 2005–2010 from
the 2008 revision of the population database of the United
Nations Population Division [18] and added estimates of still-
births and induced abortions projected for 2007 [9]. The re-
ported national fertility rate for DRC from 2005 to 2010 was
used to estimate the fraction and numbers of births in each
gravidity category. We deducted 6.2% of the national estimates
of pregnancies and births to obtain the number at risk of malaria
because of the reported absence of malaria risk in this pro-
portion of DRC’s population [[15], protocol S1].
The potential impact of successful malaria control in preg-
nancy on placental malaria and LBW was estimated by using the
summary protective efficacy of ITNs and IPTp-SP obtained
from previous meta-analyses of randomized controlled trials:
These suggest that ITNs and IPTp-SP can reduce the prevalence
of malaria at delivery among all gravidae by 24% and 57%,
respectively [4, 19, 20]. Additionally, ITNs or IPTp-SP have been
shown to reduce the prevalence of LBW among primi- and
secundigravidae (G1/2) by 23% [7] and 29% [4], respectively.
We estimated that microscopy would detect 68% of PCR-
detectable parasitemias, based on a previous study of Congolese
pregnant women using identical PCR protocols [21].
The prevalence estimates of LBW, combined with the absolute
number of pregnancies at risk per gravidity group, were then
used to compute the number of births resulting in LBW, which
in turn was used to estimate the number that could be prevented
by successful malaria control in pregnancy. Because IPTp-SP is
provided in the second and third trimester only, the number of
births was used for these impact estimates. We estimated the
impact of IPTp-SP and ITNs on LBW in the first 2 pregnancies
only. In order to indirectly obtain the number of LBW births to
G1/2 only, we combined national estimates of the prevalence of
LBW in all gravidae in DRC in 2007 (reported as 12.5% by the
World Health Organization Department of Making Pregnancy
Safer [22]) with data on the relative distribution of LBW by
these gravidae groups obtained from other studies in malaria-
endemic areas and with the number of annual births in these
strata obtained from demographic data [3, 9]. The summary
relative risk of LBW among G1/2 versus G31 (2.06) was ob-
tained from a random effect meta-analysis model using data
from 6 observational studies in malaria-endemic areas in Africa
since 1997 [23–28]. These studies were identified using the
Malaria in Pregnancy Library [29], and meta-analysis was per-
formed using Comprehensive Meta-Analysis (version 2.0, Bio-
stat, Englewood, NJ).
RESULTS
Overall, 9995 WOCBA were surveyed, of which 1100 (11.0%)
reported to be pregnant. Because the survey was designed to
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collect blood samples from only half of the women, biometric
data were available from 4570 WOCBA, of whom 520 (11.3%;
95% confidence interval [CI], 10.0–12.6) reported being
currently pregnant. These 4570 women constituted the
sample of analysis, and there were no significant differences
in age, residence, bednet use, pregnancy, or wealth between
women with and without blood samples collected (data not
shown).
Among the subset of 2669 WOCBA queried about bednets,
bednet use the night prior to the interview was infrequent
(23.4%; 95% CI, 21.1–25.7) either with an ITN (6.6%; 95% CI,
5.3–7.9) or an untreated net (16.8%; 95% CI, 14.8–18.8); use
was highly variable between clusters [17]. Similar use was re-
ported when the analysis was restricted to pregnant women
(data available for 390): only 7.0% (95% CI, 2.5–11.4) reported
using an ITN and 14.6% (95% CI, 10.0–19.2) reported the use of
an untreated net. There were no data regarding bednet source,
antenatal care, or the use of antenatal antimalarials.
Prevalence of Parasitemia
The overall prevalence of malaria parasitemia among WOCBA
was 31.2% (95% CI, 29.2–33.1), and this was 37.2% among the
520 pregnant women (95%CI, 31.0–43.5) compared with 30.4%
(95% CI, 28.4–32.5) among the nonpregnant women (PR, 1.22;
95% CI, 1.02–1.47) (Table 1).
P. falciparum accounted for most infections (95.3%) and
P. malariae and P. ovale monoinfections for most of the re-
mainder (Figure 3). While the prevalence of P. falciparum was
higher among pregnant women (36.6%) than their nonpregnant
(28.8%) peers (PR, 1.27; 95% CI, 1.05–1.53), P. malariae was
Figure 2. Schematic approach to the extrapolation of survey results to PAM burden and control estimates.Abbreviations: PAM, pregnancy-associated malaria;
DRC, Democratic Republic of the Congo; G1/2, primi- and secundigravidae; ITN, insecticide-treated bednet; IPTp-SP, intermittent preventive therapy with
sulfadoxine-pyrimethamine; LBW: low birth weight.a References [9, 15, 18].b Reference [16].c Reference [9].d Reference [7].e Reference [4].f Reference [17].g
References [4, 19].h Reference [20].
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less common in pregnant (0.6%) compared with nonpregnant
(2.7%) women (PR, 0.23; 95% CI, 0.09–0.56). Nevertheless,
among parasitemic women, the overall distribution of infecting
species did not differ significantly between pregnant and non-
pregnant women (Fisher exact P value .222). P. ovale was rare




Among 4050 women who were not currently pregnant, bivariate
analyses demonstrated that malaria parasitemia was significantly
associated only with urban (compared with rural) residence and
all wealth quintiles below the highest (Table 2). In a multivariate
model, only increasing age and increasing wealth quintiles were
significantly associated with lower prevalences of parasitemia.
Pregnant Women
Among 520 pregnant women, bivariate analyses demonstrated
that gravidity, trimester of pregnancy, and increasing age were
inversely associated with the prevalence of parasitemia (Table 2).
In primigravidae, parasite prevalence increased from the first to
the third trimester, while in multigravidae, the parasite preva-
lence decreased with increasing gestation (interaction term
P value 5 .3298) (Figure 4). Other predictors of malaria
included rural residence (compared with urban) and all cate-
gories of wealth below the highest quintile.
In a multivariate model incorporating the significant co-
variates as well as known risk factors for parasitemia in preg-
nancy, only lower wealth was significantly associated with higher
prevalence of parasitemia (Table 2).
Prevalence of Anemia
The prevalence of anemia was 32.3% among WOCBA (95% CI,
30.3–34.3), and was more common in pregnant women (56.4%;
95% CI, 50.2–62.7) than in nonpregnant (29.1%; 95% CI, 27.1–
31.2) women (PR, 1.94; 95% CI, 1.7–2.2). Mean Hgb among
WOCBA was 11.6 g/dL, and was significantly lower in pregnant
(10.6 g/dL) than nonpregnant (11.8 g/dL) women (P , .001).
The prevalence of severe anemia (Hgb, 7 g/dL) was 1.1% (95%
CI, 0.7–1.5) among WOCBA, and was more prevalent in preg-
nant women (2.7%; 95% CI, 0.9–4.5) than nonpregnant (0.6%;
95% CI, 0.3–0.9) women (PR, 4.5; 95% CI, 1.9–10.7).
Predictors of Anemia in Pregnant Women
Among 516 pregnant women who had Hgb measurements,
malaria parasitemia was associated with a small increased
prevalence of anemia (PR, 1.09; 95% CI, 0.87–1.37) and severe
anemia (PR, 1.2; 95% CI, 0.41–3.51) (Table 3). In a multivariate
Table 1. Parasitemias Among Pregnant and Nonpregnant Women
All WOCBA, % (n 5 4570) Pregnant, % (n 5 520) Nonpregnant, % (n 5 4050) PRa p valuea
P. falciparum b 29.7 (27.8–31.6) 36.6 (30.3–42.9) 28.8 (26.8–30.8) 1.27 (1.05–1.53) .0114
P. malariae b 0.6 (0.1–1.2) 0.6 (0.08–1.2) 2.7 (2–3.5) 0.23 (0.09–0.56) .0015
P. ovale b 0.5 (0.2–0.8) 0.7 (0–1.6) 0.5 (0.1–0.8) 1.49 (0.36–6.09) .5781
Any species 31.2 (29.2–33.1) 37.2 (31–43.5) 30.4 (28.4–32.5) 1.22 (1.02–1.47) .0284
Abbreviations: WOCBA, women of childbearing age; PR, prevalence ratio. Proportions and prevalence ratios were calculated using sampling weights. Values are
percentages; those in parentheses are 95% confidence intervals.
a For comparison of pregnant versus nonpregnant women; calculated using Poisson regression.
b Includes mixed-species infections.
Figure 3. Infecting Plasmodium species among parasitemic pregnant and nonpregnant women.
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Table 2. Bivariate and Multivariate Models of the Risk of Malaria Parasitemia (any Species) Among All WOCBA, Pregnant, and
Nonpregnant Women
No. of women Parasitemic, % (95% CI) PR (95% CI) PR P value aPRa (95% CI) aPR P valuea
All WOCBA (n 5 4570)
Age
15–24 1932 34.1 (31.1–37.1) REF .0357 REF .008
25–34 1407 28.4 (24.9–31.8) 0.83 (0.72–0.97) 0.82 (0.70–0.95)
35–49 1231 29.7 (25.9–33.6) 0.87 (0.75–1.02) 0.83 (0.71–0.97)
HIV
Negative 449 31.4 (29.4–33.4) REF .0889 REF .1683
Positive 179 15.9 (3.4–28.3) 0.51 (0.23–1.11) 0.58 (0.27–1.26)
Residence
Urban 2195 24.9 (22.4–27.3) REF ,.0001 REF .2484
Rural 2375 36.3 (33.4–39.3) 1.46 (1.29–1.66) 0.91 (0.76–1.07)
Wealth index
Highest 1090 13.9 (11.6–16.2) REF ,.0001 REF ,.0001
High 946 30.4 (26.3–34.5) 2.18 (1.76–2.7) 2.23 (1.79–2.77)
Moderate 870 35.1 (30.1–40.1) 2.52 (2.02–3.14) 2.70 (2.11–3.45)
Low 812 41.0 (36.1–46.0) 2.94 (2.4–3.62) 3.23 (2.51–4.14)
Lowest 852 37.7 (32.8–42.6) 2.71 (2.19–3.34) 2.96 (2.27–3.86)
Currently pregnant
No 4050 30.4 (28.4–32.5) REF .0284 REF .1886
Yes 520 37.2 (31.0–43.5) 1.22 (1.02–1.47) 1.13 (0.94–1.35)
Pregnant women (n 5 520)
Age
15–24 237 42.6 (33.3–52.0) REF .2993 REF .5814
25–34 207 32.8 (22.6–42.9) 0.77 (0.53–1.12) 0.81 (0.54–1.21)
35–49 76 32.1 (16.6–47.3) 0.75 (0.44–1.28) 0.87 (0.51–1.50)
HIV
Negative 514 37.4 (31.1–43.7) REF .1557 REF .4072
Positive 6 8.3 (0–25.6) 0.22 (0.03–1.77) 0.43 (0.06–3.16)
Residence
Urban 207 30.1 (20.8–39.3) REF .821 REF .7615
Rural 313 41.6 (33.3–50.0) 1.38 (0.96–2) 0.94 (0.63–1.41)
Wealth index
Highest 78 12.0 (4.0–20.1) REF .0002 REF .0009
High 107 31.5 (18.4–44.5) 2.61 (1.19–5.73) 2.58 (1.16–5.75)
Moderate 116 52.5 (39.0–65.9) 4.36 (2.13–8.9) 4.24 (1.94–9.24)
Low 99 49.3 (34.1–64.5) 4.1 (1.96–8.53) 4.16 (1.87–9.24)
Lowest 120 30.7 (19.2–42.1) 2.55 (1.19–5.47) 2.47 (1.06–5.75)
Gravidity
Primigravidae 110 43.7 (30.4–57.0) REF .5501 REF .5101
Secundigravidae 81 34.2 (18.9–49.5) 0.78 (0.46–1.34) 0.74 (0.44–1.24)
Multigravidae 329 36.3 (28.2–44.3) 0.83 (0.57–1.21) 0.93 (0.63–1.40)
Trimester
First 136 40.8 (28.1–53.4) REF .6259 REF .6701
Second 223 37.8 (28.1–47.5) 0.93 (0.62–1.39) 0.92 (0.64–1.33)
Third 161 32.9 (22.5–43.3) 0.81 (0.52–1.25) 0.83 (0.55–1.25)
Bednet use
ITN 23 48.5 (14.4–82.7) REF .3614 Not included .
Untreated 73 26.4 (12.3–40.5) 0.72 (0.40–1.28)
None 294 36.8 (28.6–45.1) 1.32 (0.63–2.75)
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model including place of residence, parasitemia was associated
with a small increased prevalence of anemia (adjusted PR, 1.07;
95% CI, 0.85–1.35).
Extrapolation of Parasite Prevalence to National Estimates
In 2007, an estimated 3.807 million pregnancies occurred in
DRC, resulting in 2.958 million births, 93.8% of which occurred
in malaria-endemic areas (3.571 million pregnancies and 2.775
million births). Given the nationally representative parasite
prevalence in pregnant women of 37.2% (95% CI, 31.0%–
43.5%) in this study, 1.328 million (95% CI, 1.107–1.553)
pregnancies and 1.032million (95%CI, 0.860–1.207) births may
be affected by malaria infection every year in DRC. The corre-
sponding figures for P. falciparum based on the prevalence of
36.6% (95% CI, 30.3–42.9) were 1.307 million (95% CI, 1.082–
1.532) pregnancies and 1.015 million (95% CI, 0.841–1.190)
births.
Approximately 68% of P. falciparum infections detected by
this real-time PCR assay are detectable by microscopy, sug-
gesting that 690 539 pregnancies resulting in births (0.68 3
1.015 million) have a P. falciparum infection detectable by mi-
croscopy. Of the 1.015 million births affected by P. falciparum,
ITNs alone could reduce the number of infections by 24% or 243
720 (PCR) and 165 729 (microscopy) births. Two-dose IPTp-SP
could reduce this by 57% or 578 834 (PCR) and 393 607 (mi-
croscopy) births. Given the low uptake of ITNs (7.1%) and
IPTp-SP (5.1%), optimal adherence to ITNs or IPTp-SP could
prevent 226 415 or 549 313 episodes of PAM, respectively.
Among 880 821 first- and second-time pregnancies, 169
704 were estimated to deliver LBW newborns. ITNs have the
potential to reduce LBW by 23% in primi- and secundi-
gravidae, or 39 032 births, and IPTp-SP by 29%, or 49 214
births. ITN coverage among pregnant women during the
survey was only 7% (see above), potentially preventing only
2771 LBW births; increasing this to 100% would thus prevent
an additional 36 261 LBW births. Increasing the coverage of
IPTp-SP from the reported 5.1% [3, 16] to the Roll Back
Malaria initiative target of 100% would result in an addi-
tional 46 704 LBW births prevented among women in their
first and second pregnancies.
Table 2 continued.
No. of women Parasitemic, % (95% CI) PR (95% CI) PR P value aPRa (95% CI) aPR P valuea
Nonpregnant WOCBA (n 5 4050)
Age
15–24 1695 32.9 (29.7–36.1) REF .0917 REF .0166
25–34 1200 27.6 (24.0–31.2) 0.84 (0.71–0.99) 0.82 (0.70–0.96)
35–49 1155 29.6 (25.6–33.6) 0.90 (0.76–1.06) 0.83 (0.71–0.98)
HIV
Negative 3977 30.7 (28.6–32.7) REF .1165 REF .1768
Positive 73 16.2 (3.3–29.0) 0.53 (0.24–1.17) 0.59 (0.27–1.27)
Residence
Urban 1988 24.3 (21.8–26.9) REF ,.0001 0.89 (0.74–1.07) .2213
Rural 2062 35.6 (32.5–38.7) 1.46 (1.28–1.68) 0.89 (0.74–1.07)
Wealth index
Highest 1012 14.1 (11.7–16.5) REF ,.0001 REF ,.0001
High 839 30.2 (25.9–34.5) 2.14 (1.72–2.68) 2.22 (1.78–2.79)
Moderate 754 32.6 (27.3–37.9) 2.31 (1.83–2.93) 2.55 (1.96–3.32)
Low 713 40.0 (34.8–45.2) 2.84 (2.29–3.52) 3.19 (2.44–4.16)
Lowest 732 38.8 (33.5–44.1) 2.76 (2.21–3.43) 3.11 (2.35–4.11)
Abbreviations: WOCBA, women of childbearing age; PR, prevalence ratio; aPR, adjusted prevalence ratio; REF, reference group; HIV, human immunodeficiency
virus. The wealth index was a household score of goods owned and lodging characteristics that was subsequently partitioned into quintiles. All proportions, PR, and
aPR were calculated using sampling weights.
a Results of multivariate Poisson regression model, including all covariates for which aPR values are listed.
Figure 4. Parasite prevalence by gravidity and trimester among 520
pregnant women. Parasitemias include any malaria species. Values are
percentages; those in parentheses are 95% confidence intervals.
Gravidity and trimester determined by self-report. Overall differences in
proportions were nonsignificant in a Poisson regression model. All
analyses calculated using sampling weights.
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DISCUSSION
In this population-based cross-sectional survey, the prevalence
of malaria parasitemia in pregnant women was over 37%, and
was significantly more common than in nonpregnant women of
childbearing age. P. falciparum accounted for most parasitemias
in both groups; though, interestingly, P. malariae was more
prevalent in nonpregnant WOCBA than pregnant women. The
overall prevalence of parasitemia translates into 1.3 million
pregnancies affected per year, or approximately 1 million births.
Uptake of PAM-preventive measures was very low, and optimal
adherence could prevent between 36 000 to 47 000 LBW births
annually. Because these estimates are based on a point-
prevalence of parasitemia, the rate of PAM and the benefit of
preventive measures in DRC are likely to be greater.
Quantifying the burden of PAM and the number of infected
pregnant women is critical to evaluate the implementation of
proven preventive measures. Recent developments in the
methodology of spatial epidemiology of malaria endemicity [30]
have enabled improved estimation of the number of pregnancies
at potential risk of malaria [9], though no studies have yet
supplied the number of pregnancies affected by malaria using
a nationally representative sample to generate better estimates of
PAM burden. As such, our study adds to the understanding of
both the epidemiology and consequences of PAM in DRC, as
well as the potential benefits of preventing it.
The low coverage of proven measures such as IPTp-SP and
ITNs to prevent PAM represent one of the largest missed op-
portunities of programs to prevent maternal and newborn death
in sub–Saharan Africa [31], particularly in DRC [3]. DRC PAM
prevention policy endorsed IPTp-SP in 2004 and ITNs in 2006.
The uptake is anticipated to improve considerably over the
coming years with incipient financial support by the Global
Fund to Fight AIDS, Tuberculosis and Malaria, and the U.S.
President’s Malaria Initiative. We have used the extant gap in
coverage to estimate the morbidity reductions possible with
enhanced uptake of ITNs and IPTp-SP, using published esti-
mates of the protective efficacy of such measures. The estimated
Table 3. Bivariate and Multivariate Models of the Risk of Moderate Anemia (Hgb < 11 g/dL) Among 516 Pregnant Women
No. of women Anemic, % (95% CI) PR (95% CI) PR P value aPR a (95% CI) aPR P valuea
Age
15–24 236 56.0 (46.5–65.4) REF .226 Not included .
25–34 204 61.2 (51.4–71.0) 1.09 (0.87–1.38)
35–49 76 44.0 (28.8–59.2) 0.79 (0.54–1.15)
HIV
Negative 514 56.4 (50.1–62.7) REF .3413 Not included .
Positive 6 74.3 (32.9–100) 1.32 (0.75–2.32)
Residence
Urban 207 50.2 (40.7–59.8) REF .1233 REF .1449
Rural 313 60.3 (52.2–68.4) 1.20 (0.95–1.51) 1.19 (0.94–1.51)
Wealth index
Highest 78 62.0 (49.2–74.8) REF .3899 Not included .
High 107 43.8 (30.6–57.0) 0.71 (0.49–1.02)
Moderate 116 61.4 (48.7–74.1) 0.99 (0.74–1.33)
Low 99 59.8 (45.0–74.7) 0.96 (0.70–1.33)
Lowest 120 57.6 (44.3–70.9) 0.93 (0.68–1.27)
Gravidity
Primigravidae 110 58.9 (45.4–72.4) REF .6077 Not included .
Secundigravidae 81 62.1 (46.8–77.3) 1.05 (0.75–1.47)
Multigravidae 329 54.2 (46.3–62.1) 0.92 (0.70–1.21)
Trimester
First 136 46.0 (33.3–58.8) REF .2002 Not included .
Second 223 61.4 (51.7–71.1) 1.33 (0.97–1.83)
Third 161 58.9 (48.1–69.6) 1.28 (0.92–1.78)
Malaria parasitemia
No 354 54.6 (47.0–62.3) REF .4481 REF .5571
Yes 166 59.7 (48.9–70.4) 1.09 (0.87–1.37) 1.07 (0.85–1.35)
Abbreviations: Hgb, hemoglobin, PR, prevalence ratio; aPR, adjusted prevalence ratio; REF, reference group; HIV, human immunodeficiency virus. The wealth index
was a household score of good owned and lodging characteristics that was subsequently partitioned into quintiles. All proportions, PR, and aPR calculated using
sampling weights.
a Results of multivariate Poisson regression model.
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36 000 to 47 000 LBW births that could be prevented every year
in the DRC by full adherence to ITNs or IPTp-SP, respectively,
represents a substantial opportunity to improve childhood
health in a country that suffers the fifth-largest global burden of
neonatal deaths [32].
On an individual level, we observed differences in the prev-
alences of parasitemia and anemia consonant with traditional
risk factors, though these differences did not generally achieve
statistical significance. Regarding parasitemia, we note a differ-
ential effect of gravidity and gestational age on parasitemia,
whereby, as gestational age increased, parasitemia was less
prevalent in multigravidae and more prevalent in primigravidae.
Nevertheless, these differences did not achieve statistical signif-
icance, and given the cross-sectional nature of the study and the
lack of sufficient antenatal care information, we are unable to
study this relationship rigorously. Although we found that
pregnancy was associated with increased risk of parasitemia in
the univariate analysis, the effect was smaller and nonsignificant
in our multivariate models. Possible explanations include the
miscategorization of women as nonpregnant when in the early
stage of pregnancy, or the use of IPTp and ITNs by a small but
significant number of women.
Two other findings merit further attention. First, HIV in-
fection was inversely associated with the prevalence of para-
sitemia, in contrast with most other studies in sub–Saharan
Africa in which the risk of parasitemia is greater in HIV-infected
patients [33, 34]. This relationship was consistent in subanalyses
of pregnant and nonpregnant women, and in multivariate
models incorporating available potential confounders of the re-
lationship. The lack of additional clinical or laboratory data pre-
vents further exploration, though more frequent use of
antimalarials or adherence to daily cotrimoxazole prophylaxis
could account for the reduced risk, as recently reported in Malawi
[35]. Women were not specifically queried regarding the use of
cotrimoxazole. Second, among all WOCBA, P. malariae was
significantly less prevalent among pregnant women compared
with nonpregnant women. To our knowledge, this relationship
has not previously been demonstrated, though because of the
focal spatial distribution of P. malariae [17], we cannot rule out
confounding by the parasite’s limited geographic transmission.
As expected, anemia was substantial among pregnant women,
though was not associated with parasitemia, perhaps owing to
the use of PCR for parasite detection (which detects low-level
parasitemias). Very few women suffered from severe anemia, in
contrast to women in other malarious African settings [36].
Given the multiple etiologies of anemia in similar populations
[37], the lack of additional nutritional and biometric data points
precluded a more detailed causal analysis of the effect of para-
sitemia on anemia.
Our cross-sectional molecular survey of women of child-
bearing age has several limitations. Part of the survey was
conducted during the drier season, which may underestimate
year-round prevalence. Without longitudinal data, we cannot
directly assess the effect of individual parasitemias on birth
outcomes in our survey respondents. Thus, we have used esti-
mates of the individual consequences of PAM derived from
prior studies to estimate the burden of the population-level
consequences of PAM. Additionally, we employed a sensitive
PCR assay that detects substantially more parasitemias than
microscopy [21], though the clinical significance of such ‘‘sub-
microscopic’’ parasitemias is uncertain [38, 39]. Nevertheless,
the increased prevalence in pregnant women and the association
with gravidity suggest that such parasitemias represent a genu-
ine biological consequence of pregnancy. We relied upon self-
report for determination of pregnancy status. Though sub-
optimal, familiarity with pregnancy was high in the surveyed
women, suggesting reliability. Finally, no data were available
regarding antenatal care or the use of IPTp, preventing as-
sessment of their effect on parasitemia.
To our knowledge, these are the first data to estimate the
infection risk, potential consequences, and potential benefits of
the control of PAM on a national scale using representative data.
Though our data highlight an untoward gap between PAM
policies and practices in one of the most intensely malarious
regions on earth, they also suggest a means by which DRC and
similar countries may achieve substantial improvements in
maternal and child health.
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